Table 3.
Changes in Clinical Research Endpoints After −9 minutes Shift of the CGM Measurements.
| Research endpoint | CGM | CGMshift | Changeb |
|---|---|---|---|
| Level 1 hypoglycemia (PG ≤ 70 mg/dL) | |||
| Sensitivity | 35.7% | 41.6% | 5.9% c |
| Specificity | 97.5% | 98.1% | 0.6% c |
| Level 2 hypoglycemia (PG < 54 mg/dL) | |||
| Sensitivity | 44.8% | 56.2% | 11.4% c |
| Specificity | 99.4% | 99.4% | +0.0% c |
| Postprandial glucose (mg/dL) | |||
| 30 min MADa | 27.9 | 23.0 | –4.9 |
| 60 min MADa | 30.8 | 27.6 | –3.2 |
| 120 min MADa | 32.3 | 29.2 | –3.1 |
| 180 min MADa | 26.7 | 23.8 | –2.9 |
The Reference to CGM is the PG Measurements from Blood Samples. aMean absolute difference between CGM and PG postprandial glucose increments. Notice that the assumption is that the PG value and timing is the truth. bAll changes marked with bold are improvements. C%-point change.